Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: An effect controlled by the thioredoxin system

Yu Sun, Leahana M. Rowehl, Liqun Huang, Gerardo Mackenzie, Kvetoslava Vrankova, Despina Komninou, Basil Rigas

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Introduction: We have recently synthesized phospho-ibuprofen (P-I; MDC-917), a safer derivative of ibuprofen, which has shown anti-cancer activity. We investigated its efficacy and mechanism of action in the treatment of breast cancer in preclinical models.Methods: We evaluated the anti-breast-cancer efficacy of P-I alone or incorporated into liposomes (Lipo-P-I) in human estrogen receptor-positive (MCF-7) and triple-negative, i.e., estrogen receptor-negative, progesterone receptor-negative and HER2-negative (MDA-MB231) breast cancer cell lines - as they represent the most frequent (estrogen receptor-positive) and the most difficult-to-treat (triple-negative) subtypes of breast cancer - and their xenografts in nude mice. We assessed the effect of P-I on the levels of reactive oxygen nitrogen species in response to P-I using molecular probes, on the thioredoxin system (expression and redox status of thioredoxin-1 (Trx-1) and thioredoxin reductase activity), on cyclooxygenase 2, NF-κB and mitogen-activated protein kinase cell signaling; and on the growth of xenografts with stably knocked-down Trx-1.Results: Compared with controls, P-I 400 mg/kg/day inhibited the growth of MDA-MB231 xenografts by 266%, while the growth of MCF-7 xenografts was inhibited 51% byP-I 300 mg/kg/day and 181% by Lipo-P-I 300 mg/kg/day. In both cell lines, P-I induced oxidative stress and suppressed the thioredoxin system (oxidized Trx-1 and decreased its expression; inhibited thioredoxin reductase activity). These changes triggered downstream redox signaling: the activity of NF-κB was suppressed and the Trx-1-ASK1 complex was dissociated, activating the p38 and JNK mitogen-activated protein kinase cascades. Trx-1 knockdown abrogated the anti-cancer effect of P-I in vitro and in vivo.Conclusion: P-I is safe and effective against breast cancer. Liposomal formulation enhances its efficacy; the effect is heavily dependent on the induction of oxidative stress and the suppression of the thioredoxin system. P-I merits further evaluation as an agent for the treatment of breast cancer.

Original languageEnglish (US)
Article numberR20
JournalBreast Cancer Research
Volume14
Issue number1
DOIs
StatePublished - Jan 31 2012
Externally publishedYes

Fingerprint

Thioredoxins
Breast Neoplasms
Growth
Heterografts
Estrogen Receptors
Thioredoxin-Disulfide Reductase
Oxidation-Reduction
Oxidative Stress
Triple Negative Breast Neoplasms
Reactive Nitrogen Species
Molecular Probes
Cell Line
2-(4-isobutylphenyl)propionic acid 4-(diethoxyphosphoryloxy)butyl ester
JNK Mitogen-Activated Protein Kinases
Ibuprofen
p38 Mitogen-Activated Protein Kinases
Progesterone Receptors
Cyclooxygenase 2
Mitogen-Activated Protein Kinases
Nude Mice

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phospho-ibuprofen (MDC-917) suppresses breast cancer growth : An effect controlled by the thioredoxin system. / Sun, Yu; Rowehl, Leahana M.; Huang, Liqun; Mackenzie, Gerardo; Vrankova, Kvetoslava; Komninou, Despina; Rigas, Basil.

In: Breast Cancer Research, Vol. 14, No. 1, R20, 31.01.2012.

Research output: Contribution to journalArticle

Sun, Yu ; Rowehl, Leahana M. ; Huang, Liqun ; Mackenzie, Gerardo ; Vrankova, Kvetoslava ; Komninou, Despina ; Rigas, Basil. / Phospho-ibuprofen (MDC-917) suppresses breast cancer growth : An effect controlled by the thioredoxin system. In: Breast Cancer Research. 2012 ; Vol. 14, No. 1.
@article{598eb65539fe41a7ad371d1ff0254ade,
title = "Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: An effect controlled by the thioredoxin system",
abstract = "Introduction: We have recently synthesized phospho-ibuprofen (P-I; MDC-917), a safer derivative of ibuprofen, which has shown anti-cancer activity. We investigated its efficacy and mechanism of action in the treatment of breast cancer in preclinical models.Methods: We evaluated the anti-breast-cancer efficacy of P-I alone or incorporated into liposomes (Lipo-P-I) in human estrogen receptor-positive (MCF-7) and triple-negative, i.e., estrogen receptor-negative, progesterone receptor-negative and HER2-negative (MDA-MB231) breast cancer cell lines - as they represent the most frequent (estrogen receptor-positive) and the most difficult-to-treat (triple-negative) subtypes of breast cancer - and their xenografts in nude mice. We assessed the effect of P-I on the levels of reactive oxygen nitrogen species in response to P-I using molecular probes, on the thioredoxin system (expression and redox status of thioredoxin-1 (Trx-1) and thioredoxin reductase activity), on cyclooxygenase 2, NF-κB and mitogen-activated protein kinase cell signaling; and on the growth of xenografts with stably knocked-down Trx-1.Results: Compared with controls, P-I 400 mg/kg/day inhibited the growth of MDA-MB231 xenografts by 266{\%}, while the growth of MCF-7 xenografts was inhibited 51{\%} byP-I 300 mg/kg/day and 181{\%} by Lipo-P-I 300 mg/kg/day. In both cell lines, P-I induced oxidative stress and suppressed the thioredoxin system (oxidized Trx-1 and decreased its expression; inhibited thioredoxin reductase activity). These changes triggered downstream redox signaling: the activity of NF-κB was suppressed and the Trx-1-ASK1 complex was dissociated, activating the p38 and JNK mitogen-activated protein kinase cascades. Trx-1 knockdown abrogated the anti-cancer effect of P-I in vitro and in vivo.Conclusion: P-I is safe and effective against breast cancer. Liposomal formulation enhances its efficacy; the effect is heavily dependent on the induction of oxidative stress and the suppression of the thioredoxin system. P-I merits further evaluation as an agent for the treatment of breast cancer.",
author = "Yu Sun and Rowehl, {Leahana M.} and Liqun Huang and Gerardo Mackenzie and Kvetoslava Vrankova and Despina Komninou and Basil Rigas",
year = "2012",
month = "1",
day = "31",
doi = "10.1186/bcr3105",
language = "English (US)",
volume = "14",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Phospho-ibuprofen (MDC-917) suppresses breast cancer growth

T2 - An effect controlled by the thioredoxin system

AU - Sun, Yu

AU - Rowehl, Leahana M.

AU - Huang, Liqun

AU - Mackenzie, Gerardo

AU - Vrankova, Kvetoslava

AU - Komninou, Despina

AU - Rigas, Basil

PY - 2012/1/31

Y1 - 2012/1/31

N2 - Introduction: We have recently synthesized phospho-ibuprofen (P-I; MDC-917), a safer derivative of ibuprofen, which has shown anti-cancer activity. We investigated its efficacy and mechanism of action in the treatment of breast cancer in preclinical models.Methods: We evaluated the anti-breast-cancer efficacy of P-I alone or incorporated into liposomes (Lipo-P-I) in human estrogen receptor-positive (MCF-7) and triple-negative, i.e., estrogen receptor-negative, progesterone receptor-negative and HER2-negative (MDA-MB231) breast cancer cell lines - as they represent the most frequent (estrogen receptor-positive) and the most difficult-to-treat (triple-negative) subtypes of breast cancer - and their xenografts in nude mice. We assessed the effect of P-I on the levels of reactive oxygen nitrogen species in response to P-I using molecular probes, on the thioredoxin system (expression and redox status of thioredoxin-1 (Trx-1) and thioredoxin reductase activity), on cyclooxygenase 2, NF-κB and mitogen-activated protein kinase cell signaling; and on the growth of xenografts with stably knocked-down Trx-1.Results: Compared with controls, P-I 400 mg/kg/day inhibited the growth of MDA-MB231 xenografts by 266%, while the growth of MCF-7 xenografts was inhibited 51% byP-I 300 mg/kg/day and 181% by Lipo-P-I 300 mg/kg/day. In both cell lines, P-I induced oxidative stress and suppressed the thioredoxin system (oxidized Trx-1 and decreased its expression; inhibited thioredoxin reductase activity). These changes triggered downstream redox signaling: the activity of NF-κB was suppressed and the Trx-1-ASK1 complex was dissociated, activating the p38 and JNK mitogen-activated protein kinase cascades. Trx-1 knockdown abrogated the anti-cancer effect of P-I in vitro and in vivo.Conclusion: P-I is safe and effective against breast cancer. Liposomal formulation enhances its efficacy; the effect is heavily dependent on the induction of oxidative stress and the suppression of the thioredoxin system. P-I merits further evaluation as an agent for the treatment of breast cancer.

AB - Introduction: We have recently synthesized phospho-ibuprofen (P-I; MDC-917), a safer derivative of ibuprofen, which has shown anti-cancer activity. We investigated its efficacy and mechanism of action in the treatment of breast cancer in preclinical models.Methods: We evaluated the anti-breast-cancer efficacy of P-I alone or incorporated into liposomes (Lipo-P-I) in human estrogen receptor-positive (MCF-7) and triple-negative, i.e., estrogen receptor-negative, progesterone receptor-negative and HER2-negative (MDA-MB231) breast cancer cell lines - as they represent the most frequent (estrogen receptor-positive) and the most difficult-to-treat (triple-negative) subtypes of breast cancer - and their xenografts in nude mice. We assessed the effect of P-I on the levels of reactive oxygen nitrogen species in response to P-I using molecular probes, on the thioredoxin system (expression and redox status of thioredoxin-1 (Trx-1) and thioredoxin reductase activity), on cyclooxygenase 2, NF-κB and mitogen-activated protein kinase cell signaling; and on the growth of xenografts with stably knocked-down Trx-1.Results: Compared with controls, P-I 400 mg/kg/day inhibited the growth of MDA-MB231 xenografts by 266%, while the growth of MCF-7 xenografts was inhibited 51% byP-I 300 mg/kg/day and 181% by Lipo-P-I 300 mg/kg/day. In both cell lines, P-I induced oxidative stress and suppressed the thioredoxin system (oxidized Trx-1 and decreased its expression; inhibited thioredoxin reductase activity). These changes triggered downstream redox signaling: the activity of NF-κB was suppressed and the Trx-1-ASK1 complex was dissociated, activating the p38 and JNK mitogen-activated protein kinase cascades. Trx-1 knockdown abrogated the anti-cancer effect of P-I in vitro and in vivo.Conclusion: P-I is safe and effective against breast cancer. Liposomal formulation enhances its efficacy; the effect is heavily dependent on the induction of oxidative stress and the suppression of the thioredoxin system. P-I merits further evaluation as an agent for the treatment of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84862800814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862800814&partnerID=8YFLogxK

U2 - 10.1186/bcr3105

DO - 10.1186/bcr3105

M3 - Article

C2 - 22293394

AN - SCOPUS:84862800814

VL - 14

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - R20

ER -